Search

Your search keyword '"Agewall S."' showing total 18,312 results
Start Over "Agewall S."

Refine your results

more »

more »

more »

more »

more »

more »

more »
18,312 results on '"Agewall S."'

153. Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis.

Author

Deyab G, Reine TM, Vuong TT, Jenssen T, Hjeltnes G, Agewall S, Mikkelsen K, Førre Ø, Fagerland MW, Kolset SO, and Hollan I

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Endothelial Cells drug effects, Endothelial Cells metabolism, Female, Humans, Male, Matrix Metalloproteinase 9 metabolism, Methotrexate therapeutic use, Middle Aged, Prospective Studies, Tissue Inhibitor of Metalloproteinase-1 metabolism, Treatment Outcome, Young Adult, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid metabolism, Syndecan-1 metabolism
Abstract

The endothelial glycocalyx (EG) is essential for proper function of the endothelium and for vascular integrity, but its role in premature atherogenesis in rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a role in pathogenesis of vascular disease, and one of its characteristics is shedding of syndecan-1 from endothelial cells. Syndecan-1 shedding is mediated by matrix metalloproteinase-9 (MMP-9) and counteracted by tissue inhibitor of metalloproteinases (TIMP)-1. Cardiovascular disease risk in RA is reversible by disease modifying antirheumatic drugs (DMARDs), but the exact modes of action are still unclear. Therefore, we examined effects of DMARDs on syndecan-1, MMP-9 and TIMP-1 in RA patients, and searched for associations between these parameters and inflammatory activity. From the observational PSARA study, we examined 39 patients starting with methotrexate (MTX) monotherapy (in MTX naïve patients, n = 19) or tumor necrosis factor inhibitors (TNFi) in combination with MTX (in MTX non-responders, n = 20) due to active RA. Serum syndecan-1, MMP-9 and TIMP-1 were measured at baseline and after six weeks of treatment. Serum syndecan-1 (p = 0.008) and TIMP-1 (p<0.001) levels decreased after six weeks of anti-rheumatic treatment. Levels of MMP-9 also decreased, but the difference was not statistically significant. The improvement in syndecan-1 levels were independent of changes in inflammatory activity. There was no significant difference in changes in syndecan-1 levels from baseline to 6 weeks between the MTX and TNFi groups, however the change was significant within the MTX group. Six weeks of antirheumatic treatment was associated with reduction in serum levels of syndecan-1, which might reflect reduced syndecan-1 shedding from EG. Thus, it is possible that EG-preserving properties of DMARDs might contribute to their cardioprotective effects. These effects may be at least partly independent of their anti-inflammatory actions. Our findings do not support the notion that syndecan-1 shedding in RA is mediated mainly by increased MMP-9 or decreased TIMP-9 serum concentration., Competing Interests: The authors have declared that no competing interests exist.

Published
2021
Full Text
View/download PDF

154. Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis.

Author

Nguyen THP, Fagerland MW, Deyab G, Hjeltnes G, Hollan I, Feinberg MW, Eilertsen GØ, Mikkelsen K, and Agewall S

Subjects
Adult, Biomarkers blood, Blood Sedimentation, C-Reactive Protein metabolism, Female, Humans, Male, Middle Aged, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents administration & dosage, Arthritis blood, Arthritis drug therapy, Autoimmune Diseases blood, Autoimmune Diseases drug therapy, Methotrexate administration & dosage, Natriuretic Peptide, Brain blood, Peptide Fragments blood
Abstract

Background: Patients with autoimmune arthritis (AA) are at increased risk for impaired cardiac function and heart failure. This may be partly due to the effect of inflammation in heart function. The impact of antirheumatic drugs on cardiac dysfunction in AA remains controversial. Therefore, we aimed to examine effects of antirheumatic treatment on serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in AA patients and its relationship to inflammatory markers., Methods: We examined 115 patients with AA (64 rheumatoid arthritis (RA), 31 psoriatic arthritis and 20 ankylosis spondylitis) starting with methotrexate (MTX) monotherapy or tumor necrosis factor inhibitors (TNFi) with or without MTX co-medication. NT-proBNP (measured in serum by ECLIA from Roche Diagnostics), and other clinical and laboratory parameters were evaluated at baseline, after 6 weeks and 6 months of treatment., Results: NT-proBNP levels did not change significantly after 6 weeks and 6 months of antirheumatic therapy (pbaseline-6weeks = 0.939; pbaseline-6months = 0.485), although there was a modest improvement from 6 weeks to 6 months in the MTX only treatment group (median difference = -18.2 [95% CI = -32.3 to -4.06], p = 0.013). There was no difference in the effects of MTX monotherapy and TNFi regimen on NT-proBNP levels. The changes in NT-proBNP after antirheumatic treatment positively correlated with changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Baseline NT-proBNP levels were related to baseline CRP and ESR levels, and some other established markers of disease activities in crude analyses., Conclusion: Circulating levels of NT-proBNP were related to established inflammatory markers at baseline, and the changes in NT-proBNP after antirheumatic treatment were positively related to these markers. Nevertheless, antirheumatic therapy did not seem to affect NT-proBNP levels compared to baseline, even though inflammatory markers significantly improved., Competing Interests: The authors have declared that no competing interests exist. We confirm that “This (AbbVie) does not alter our adherence to all PLOS ONE policies on sharing data and materials”.

Published
2021
Full Text
View/download PDF

155. Automatic identification of variables in epidemiological datasets using logic regression

Author

Lorenz, M.W. (Matthias W.), Abdi, N.A. (Negin Ashtiani), Scheckenbach, F. (Frank), Pflug, A. (Anja), Bulbul, A. (Alpaslan), Catapano, A.L. (Alberico), Agewall, S. (Stefan), Ezhov, M. (Marat), Bots, M.L. (Michiel), Kiechl, S. (Stefan), Orth, A. (Andreas), Norata, G.D. (Giuseppe), Empana, J.P. (Jean Philippe), Lin, H.-J. (Hung-Ju), McLachlan, S. (Stela), Bokemark, L. (Lena), Ronkainen, K. (Kimmo), Amato, M. (Mauro), Schminke, U. (Ulf), Srinivasan, S.R. (Sathanur R.), Lind, L. (Lars), Kato, A. (Akihiko), Dimitriadis, C. (Chrystosomos), Przewlocki, T. (Tadeusz), Okazaki, S. (Shuhei), Stehouwer, C.D. (Coen), Lazarevic, T. (Tatjana), Willeit, J. (Johann), Yanez, D.N. (David N.), Steinmetz, H. (helmuth), Sander, D. (Dirk), Poppert, H. (Holger), Desvarieux, M. (Moise), Ikram, M.A. (Arfan), Bevc, S. (Sebastjan), Staub, D. (Daniel), Sirtori, C.R. (Cesare R.), Iglseder, B. (Bernhard), Engström, G., Tripepi, G.L. (Giovanni), Beloqui, O. (Oscar), Lee, M.-S. (Moo-Sik), Friera, A. (Alfonsa), Xie, W. (Wuxiang), Grigore, L. (Liliana), Plichart, M. (Matthieu), Su, T.-C. (Ta-Chen), Robertson, C.M. (Christine M), Schmidt, C. (Caroline), Tuomainen, T.-P. (Tomi-Pekka), Veglia, F. (Fabrizio), Völzke, H. (Henry), Nijpels, M.G.A.A.M. (Giel), Jovanovic, A. (Aleksandar), Sacco, R.L. (Ralph L.), Franco, O.H. (Oscar), Hojs, R. (Radovan), Uthoff, H. (Heiko), Hedblad, B. (Bo), Park, H.W. (Hyun Woong), Suarez, C. (Carmen), Zhao, D. (Dong), Catapano, A. (Alberico), Ducimetiere, P. (P.), Chien, K.-L. (Kuo-Liong), Price, J.F. (Jackie F.), Bergstrom, G. (Goran), Kauhanen, J. (Jussi), Tremoli, E. (Elena), Dörr, M. (Marcus), Berenson, G. (Gerald), Papagianni, A. (Aikaterini), Kablak-Ziembicka, A. (Anna), Kitagawa, K. (Kazuo), Dekker, J.M. (Jacqueline), Stolic, R. (Radojica), Polak, J.F. (Joseph F.), Sitzer, M. (Matthias), Bickel, H. (Horst), Rundek, T. (Tatjana), Hofman, A. (Albert), Ekart, R. (Robert), Frauchiger, B. (Beat), Castelnuovo, S. (Samuela), Rosvall, M. (Maria), Zoccali, C. (Carmine), Landecho, M.F. (Manuel F.), Bae, J.-H. (Jang-Ho), Gabriel, R. (Rafael), Liu, J. (Jing), Baldassarre, D. (Damiano), Kavousi, M. (Maryam), Lorenz, M.W. (Matthias W.), Abdi, N.A. (Negin Ashtiani), Scheckenbach, F. (Frank), Pflug, A. (Anja), Bulbul, A. (Alpaslan), Catapano, A.L. (Alberico), Agewall, S. (Stefan), Ezhov, M. (Marat), Bots, M.L. (Michiel), Kiechl, S. (Stefan), Orth, A. (Andreas), Norata, G.D. (Giuseppe), Empana, J.P. (Jean Philippe), Lin, H.-J. (Hung-Ju), McLachlan, S. (Stela), Bokemark, L. (Lena), Ronkainen, K. (Kimmo), Amato, M. (Mauro), Schminke, U. (Ulf), Srinivasan, S.R. (Sathanur R.), Lind, L. (Lars), Kato, A. (Akihiko), Dimitriadis, C. (Chrystosomos), Przewlocki, T. (Tadeusz), Okazaki, S. (Shuhei), Stehouwer, C.D. (Coen), Lazarevic, T. (Tatjana), Willeit, J. (Johann), Yanez, D.N. (David N.), Steinmetz, H. (helmuth), Sander, D. (Dirk), Poppert, H. (Holger), Desvarieux, M. (Moise), Ikram, M.A. (Arfan), Bevc, S. (Sebastjan), Staub, D. (Daniel), Sirtori, C.R. (Cesare R.), Iglseder, B. (Bernhard), Engström, G., Tripepi, G.L. (Giovanni), Beloqui, O. (Oscar), Lee, M.-S. (Moo-Sik), Friera, A. (Alfonsa), Xie, W. (Wuxiang), Grigore, L. (Liliana), Plichart, M. (Matthieu), Su, T.-C. (Ta-Chen), Robertson, C.M. (Christine M), Schmidt, C. (Caroline), Tuomainen, T.-P. (Tomi-Pekka), Veglia, F. (Fabrizio), Völzke, H. (Henry), Nijpels, M.G.A.A.M. (Giel), Jovanovic, A. (Aleksandar), Sacco, R.L. (Ralph L.), Franco, O.H. (Oscar), Hojs, R. (Radovan), Uthoff, H. (Heiko), Hedblad, B. (Bo), Park, H.W. (Hyun Woong), Suarez, C. (Carmen), Zhao, D. (Dong), Catapano, A. (Alberico), Ducimetiere, P. (P.), Chien, K.-L. (Kuo-Liong), Price, J.F. (Jackie F.), Bergstrom, G. (Goran), Kauhanen, J. (Jussi), Tremoli, E. (Elena), Dörr, M. (Marcus), Berenson, G. (Gerald), Papagianni, A. (Aikaterini), Kablak-Ziembicka, A. (Anna), Kitagawa, K. (Kazuo), Dekker, J.M. (Jacqueline), Stolic, R. (Radojica), Polak, J.F. (Joseph F.), Sitzer, M. (Matthias), Bickel, H. (Horst), Rundek, T. (Tatjana), Hofman, A. (Albert), Ekart, R. (Robert), Frauchiger, B. (Beat), Castelnuovo, S. (Samuela), Rosvall, M. (Maria), Zoccali, C. (Carmine), Landecho, M.F. (Manuel F.), Bae, J.-H. (Jang-Ho), Gabriel, R. (Rafael), Liu, J. (Jing), Baldassarre, D. (Damiano), and Kavousi, M. (Maryam)

Abstract

Background: For an individual participant data (IPD) meta-analysis, multiple datasets must be transformed in a consistent format, e.g. using uniform variable names. When large numbers of datasets have to be processed, this can be a time-consuming and error-prone task. Automated or semi-automated identification of variables can help to reduce the workload and improve the data quality. For semi-automation high sensitivity in the recognition of matching variables is particularly important, because it allows creating software which for a target variable presents a choice of source variables, from which a user can choose the matching one, with only low risk of having missed a correct source variable. Methods: For each variable in a set of target variables, a number of simple rules were manually created. With logic regression, an optimal Boolean combination of these rules was searched for every target variable, using a random subset of a large database of epidemiological and clinical cohort data (construction subset). In a second subset of this database (validation subset), this optimal combination rules were validated. Results: In the construction sample, 41 target variables were allocated on average with a positive predictive value (PPV) of 34%, and a negative predictive value (NPV) of 95%. In the validation sample, PPV was 33%, whereas NPV remained at 94%. In the construction sample, PPV was 50% or less in 63% of all variables, in the validation sample in 71% of all variables. Conclusions: We demonstrated that the application of logic regression in a complex data management task in large epidemiological IPD meta-analyses is feasible. However, the performance of the algorithm is poor, which may require backup strategies.

Published
2017
Full Text
View/download PDF

156. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Author

Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S.E., Torp-Pedersen, C., Kjeldsen, K., Lewis, B.S., Drexel, H., Kaski, J.C., Atar, D., Storey, R.F., Lip, G.Y., Verheugt, F.W.A., Agewall, S., Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S.E., Torp-Pedersen, C., Kjeldsen, K., Lewis, B.S., Drexel, H., Kaski, J.C., Atar, D., Storey, R.F., Lip, G.Y., Verheugt, F.W.A., and Agewall, S.

Abstract

Contains fulltext : 182909.pdf (publisher's version ) (Closed access)

Published
2017

157. 2016 European Guidelines on the Prevention of Cardiovascular Diseases in Clinical Practice Sixth Joint Task Force of the European Society of Cardiology and other Societies on the Prevention of Cardiovascular Diseases in Clinical Practice (consisting of representatives of 10 companies and invited experts) drafted with the extraordinary contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR)

Author

Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corrà, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Hobbs, F, Lochen, M, Löllgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, van der Worp, H, van Dis, I, Verschuren, W, Binno, S, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Bueno, H, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Rydén, L, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Piepoli, MF, Hoes, AW, Catapano, AL, Cooney, MT, Hall, MS, Hobbs, FDR, Lochen, ML, Richter, DJ, van der Worp, HB, Verschuren, WMM, Franco, OH, Lip, GYH, Bermudo, FM, Zamorano, JL, Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corrà, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Hobbs, F, Lochen, M, Löllgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, van der Worp, H, van Dis, I, Verschuren, W, Binno, S, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Bueno, H, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Rydén, L, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Piepoli, MF, Hoes, AW, Catapano, AL, Cooney, MT, Hall, MS, Hobbs, FDR, Lochen, ML, Richter, DJ, van der Worp, HB, Verschuren, WMM, Franco, OH, Lip, GYH, Bermudo, FM, and Zamorano, JL

Published
2017

158. Automatic identification of variables in epidemiological datasets using logic regression

Author

Lorenz, M., Abdi, N., Scheckenbach, F., Pflug, A., Bülbül, A., Catapano, A., Agewall, S., Ezhov, M., Bots, M., Kiechl, S., Orth, A., Norata, Giuseppe, Empana, J., Lin, H., McLachlan, S., Bokemark, L., Ronkainen, K., Amato, M., Schminke, U., Srinivasan, S., Lind, L., Kato, A., Dimitriadis, C., Przewlocki, T., Okazaki, S., Stehouwer, C., Lazarevic, T., Willeit, P., Yanez, D., Steinmetz, H., Sander, D., Poppert, H., Desvarieux, M., Ikram, M., Bevc, S., Staub, D., Sirtori, C., Iglseder, B., Engström, G., Tripepi, G., Beloqui, O., Lee, M., Friera, A., Xie, W., Grigore, L., Plichart, M., Su, T., Robertson, C., Schmidt, C., Tuomainen, T., Veglia, F., Völzke, H., Nijpels, G., Jovanovic, A., Willeit, J., Sacco, R., Franco, O., Hojs, R., Uthoff, H., Hedblad, B., Park, H., Suarez, C., Zhao, D., Ducimetiere, P., Chien, K., Price, J., Bergström, G., Kauhanen, J., Tremoli, E., Dörr, M., Berenson, G., Papagianni, A., Kablak-Ziembicka, A., Kitagawa, K., Dekker, J., Stolic, R., Polak, J., Sitzer, M., Bickel, H., Rundek, T., Hofman, A., Ekart, R., Frauchiger, B., Castelnuovo, S., Rosvall, M., Zoccali, C., Landecho, M., Bae, J., Gabriel, R., Liu, J., Baldassarre, D., Kavousi, M., Lorenz, M., Abdi, N., Scheckenbach, F., Pflug, A., Bülbül, A., Catapano, A., Agewall, S., Ezhov, M., Bots, M., Kiechl, S., Orth, A., Norata, Giuseppe, Empana, J., Lin, H., McLachlan, S., Bokemark, L., Ronkainen, K., Amato, M., Schminke, U., Srinivasan, S., Lind, L., Kato, A., Dimitriadis, C., Przewlocki, T., Okazaki, S., Stehouwer, C., Lazarevic, T., Willeit, P., Yanez, D., Steinmetz, H., Sander, D., Poppert, H., Desvarieux, M., Ikram, M., Bevc, S., Staub, D., Sirtori, C., Iglseder, B., Engström, G., Tripepi, G., Beloqui, O., Lee, M., Friera, A., Xie, W., Grigore, L., Plichart, M., Su, T., Robertson, C., Schmidt, C., Tuomainen, T., Veglia, F., Völzke, H., Nijpels, G., Jovanovic, A., Willeit, J., Sacco, R., Franco, O., Hojs, R., Uthoff, H., Hedblad, B., Park, H., Suarez, C., Zhao, D., Ducimetiere, P., Chien, K., Price, J., Bergström, G., Kauhanen, J., Tremoli, E., Dörr, M., Berenson, G., Papagianni, A., Kablak-Ziembicka, A., Kitagawa, K., Dekker, J., Stolic, R., Polak, J., Sitzer, M., Bickel, H., Rundek, T., Hofman, A., Ekart, R., Frauchiger, B., Castelnuovo, S., Rosvall, M., Zoccali, C., Landecho, M., Bae, J., Gabriel, R., Liu, J., Baldassarre, D., and Kavousi, M.

Abstract

Background: For an individual participant data (IPD) meta-analysis, multiple datasets must be transformed in a consistent format, e.g. using uniform variable names. When large numbers of datasets have to be processed, this can be a time-consuming and error-prone task. Automated or semi-automated identification of variables can help to reduce the workload and improve the data quality. For semi-automation high sensitivity in the recognition of matching variables is particularly important, because it allows creating software which for a target variable presents a choice of source variables, from which a user can choose the matching one, with only low risk of having missed a correct source variable. Methods: For each variable in a set of target variables, a number of simple rules were manually created. With logic regression, an optimal Boolean combination of these rules was searched for every target variable, using a random subset of a large database of epidemiological and clinical cohort data (construction subset). In a second subset of this database (validation subset), this optimal combination rules were validated. Results: In the construction sample, 41 target variables were allocated on average with a positive predictive value (PPV) of 34%, and a negative predictive value (NPV) of 95%. In the validation sample, PPV was 33%, whereas NPV remained at 94%. In the construction sample, PPV was 50% or less in 63% of all variables, in the validation sample in 71% of all variables. Conclusions: We demonstrated that the application of logic regression in a complex data management task in large epidemiological IPD meta-analyses is feasible. However, the performance of the algorithm is poor, which may require backup strategies.

Published
2017

159. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)

Author

Poldermans, D, Bax, Jj, Boersma, E, De Hert, S, Eeckhout, E, Fowkes, G, Gorenek, B, Hennerici, Mg, Iung, B, Kelm, M, Kjeldsen, Kp, Kristensen, Sd, Lopez Sendon, J, Pelosi, P, Philippe, F, Pierard, L, Ponikowski, P, Schmid, Jp, Sellevold, Of, Sicari, R, Van den Berghe, G, Vermassen, F, Hoeks, Se, Vanhorebeek, I, Vahanian, A, Auricchio, A, Ceconi, Claudio, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearn, P, Mcdonag, T, Mcgregor, K, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, P, Widimsky, P, De Caterina, R, Agewall, S, Al Attar, N, Andreotti, F, Anker, Sd, Baron Esquivias, G, Berkenboom, G, Chapoutot, L, Cifkova, R, Faggiano, P, Gibbs, S, Hansen, Hs, Iserin, L, Israel, Cw, Kornowski, R, Eizagaechevarria, Nm, Pepi, M, Piepoli, M, Priebe, Hj, Scherer, M, Stepinska, J, Taggart, D, Tubaro, M, Task Force for Preoperative Cardiac Risk Assessment, Perioperative Cardiac Management in Non cardiac Surgery of European Society of Cardiology, European Society of Anaesthesiology, Anesthesiology, and Cardiology

Subjects
Dobutamine stress echocardiography, non-cardiac surgery, GLYCOPROTEIN IIB/IIIA INHIBITION, VENTRICULAR EJECTION FRACTION, Coronary artery disease, post-operative cardiac surveillance, renal disease, AMERICAN-HEART-ASSOCIATION, POSTOPERATIVE ATRIAL-FIBRILLATION, perioperative cardiac management, Medicine and Health Sciences, neurological disease, Pre-operative cardiac risk assessment, DOBUTAMINE STRESS ECHOCARDIOGRAPHY, pulmonary disease, Pre-operative coronary artery revascularization, Post-operative cardiac surveillance, Pre operative, pre-operative cardiac testing, Non cardiac surgery, Cardiology, CORONARY-ARTERY-DISEASE, Anaesthesiology, Neurological disease, Non-cardiac surgery, Perioperative cardiac management, Pre-operative cardiac testing, Pulmonary disease, Renal disease, pre-operative cardiac risk assessment, medicine.medical_specialty, Myocardial ischemia, MAJOR VASCULAR-SURGERY, NO, CONTRAST-INDUCED NEPHROPATHY, Internal medicine, medicine, BETA-BLOCKER THERAPY, Cardiac risk, Task force, business.industry, Perioperative, medicine.disease, Anesthesiology and Pain Medicine, pre-operative coronary artery revascularization, RANDOMIZED-CONTROLLED-TRIAL, business, anaesthesiology
Abstract

ESC Committee for Practice Guidelines (CPG): Alec Vahanian (Chairperson) (France), Angelo Auricchio (Switzerland), Jeroen J. Bax (The Netherlands), Claudio Ceconi (Italy), Veronica Dean (France), Gerasimos Filippatos (Greece), Christian Funck-Brentano (France), Richard Hobbs (UK), Peter Kearney (Ire

Published
2010
Full Text
View/download PDF

160. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Author

Zamorano, JL, Lancellotti, P, Rodriguez Muñoz, D, Aboyans, V, Asteggiano, R, Galderisi, M, Habib, G, Lenihan, DJ, Lip, GY, Lyon, AR, Lopez Fernandez, T, Mohty, D, Piepoli, MF, Tamargo, J, Torbicki, A, Suter, TM, Achenbach, S, Agewall, S, Badimon, L, Barón-Esquivias, G, Baumgartner, H, Bax, JJ, Bueno, H, Carerj, S, Dean, V, Erol, Ç, Fitzsimons, D, Gaemperli, O, Kirchhof, P, Kolh, P, Nihoyannopoulos, P, Ponikowski, P, Roffi, M, Vaz Carneiro, A, Windecker, S, Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), University of Zurich, Zamorano, Jose Luis, Centre Hospitalier Universitaire de Liège (CHU-Liège), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Università degli studi di Napoli Federico II, Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), British Heart Foundation, Action Against Cancer, Zamorano, Jose Lui, Lancellotti, Patrizio, Rodriguez Muñoz, Daniel, Aboyans, Victor, Asteggiano, Riccardo, Galderisi, Maurizio, Habib, Gilbert, Lenihan, Daniel J., Lip, Gregory Y. H., Lyon, Alexander R., Lopez Fernandez, Teresa, Mohty, Dania, Piepoli, Massimo F., Tamargo, Juan, Torbicki, Adam, Suter, Thomas M., Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Barón Esquivias, Gonzalo, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Carerj, Scipione, Dean, Veronica, Erol, Çetin, Fitzsimons, Donna, Gaemperli, Oliver, Kirchhof, Paulu, Kolh, Philippe, Nihoyannopoulos, Petro, Ponikowski, Piotr, Roffi, Marco, Vaz Carneiro, António, Windecker, Stephan, Lenihan, Daniel J, Lip, Gregory Y. H, Lyon, Alexander R, Piepoli, Massimo F, University of Naples Federico II = Università degli studi di Napoli Federico II, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Vascular Endothelial Growth Factor A, Angiotensin receptor, Cardiac & Cardiovascular Systems, cardio-oncology, medicine.medical_treatment, myocardial dysfunction, 030204 cardiovascular system & hematology, ANTHRACYCLINE-INDUCED CARDIOMYOPATHY, chemotherapy, Coronary artery disease, 0302 clinical medicine, RENAL-CELL CARCINOMA, Authors/Task Force Members, Cancer Survivors, Neoplasms, Natriuretic peptide, 610 Medicine & health, early detection, ComputingMilieux_MISCELLANEOUS, Societies, Medical, HER2-POSITIVE BREAST-CANCER, TRASTUZUMAB-INDUCED CARDIOTOXICITY, Chemotherapy regimen, 3. Good health, Europe, medicine.anatomical_structure, 030220 oncology & carcinogenesis, CHEMOTHERAPY-INDUCED CARDIOTOXICITY, Practice Guidelines as Topic, cardiovascular system, Cardiology, surveillance, 10209 Clinic for Cardiology, cancer therapy, CORONARY-ARTERY-DISEASE, ESC Committee for Practice Guidelines (CPG), ischaemia, Immunotherapy, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, arrhythmias, Arrhythmia, Artery, Cardiovascular toxicity, medicine.medical_specialty, Heart Diseases, medicine.drug_class, Advisory Committees, Cancer therapy, Early detection, Antineoplastic Agents, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 1102 Cardiovascular Medicine And Haematology, 2705 Cardiology and Cardiovascular Medicine, European Society of Cardiology, 03 medical and health sciences, LEFT-VENTRICULAR DYSFUNCTION, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, TYROSINE KINASE INHIBITORS, Humans, cardiovascular diseases, Intensive care medicine, ACUTE LYMPHOBLASTIC-LEUKEMIA, Cardiotoxicity, Science & Technology, CONGESTIVE-HEART-FAILURE, Radiotherapy, business.industry, Arrhythmias, Cardio-oncology, Chemotherapy, Ischaemia, Myocardial dysfunction, Surveillance, Cancer, 10181 Clinic for Nuclear Medicine, Congresses as Topic, medicine.disease, Radiation therapy, Cardiovascular System & Hematology, Cardiovascular System & Cardiology, Position paper, business, human activities, Document Reviewers
Abstract

2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery

Published
2016
Full Text
View/download PDF

161. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Author

Zamorano, JL, Lancellotti, P, Munoz, DR, Aboyans, V, Asteggiano, R, Galderisi, M, Habib, G, Lenihan, DJ, Lyon, AR, Lopez Fernandez, T, Mohty, D, Tamargo, J, Suter, TM, Baron-Esquivias, G, Baumgartner, H, Bax, JJ, Dean, V, Kolh, P, Lip, GYH, Nihoyannopoulos, P, Piepoli, MF, Torbicki, A, Achenbach, S, Minotti, G, Agewall, S, Badimon, L, Bueno, H, Cardinale, D, Carerj, S, Curigliano, G, de Azambuja, E, Dent, S, Erol, C, Ewer, MS, Farmakis, D, Fietkau, R, Fitzsimons, D, Gaemperli, O, Kirchhof, P, Kohl, P, McGale, P, Ponikowski, P, Ringwald, J, Roffi, M, Schulz-Menger, J, Stebbing, J, Steiner, RK, Szmit, S, Carneiro, AV, and Windecker, S

Subjects
cardio-oncology, myocardial dysfunction, cardiotoxicity, surveillance, cancer therapy, ischaemia, chemotherapy, early detection, arrhythmias, European Society of Cardiology
Published
2016

162. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR)

Author

Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Additional Contributor: Simone Binno (Italy), Document Reviewers, De Backer G, Roffi M, Aboyans V, Bachl N, Bueno H, Carerj S, Cho L, Cox J, De Sutter J, Egidi G, Fisher M, Fitzsimons D, Franco OH, Guenoun M, Jennings C, Jug B, Kirchhof P, Kotseva K, Lip GY, Mach F, Mancia G, Bermudo FM, Mezzani A, Niessner A, Ponikowski P, Rauch B, Rydén L, Stauder A, Turc G, Wiklund O, Windecker S, and Zamorano JL

Published
2016

163. Linee guida ESC 2015 per il trattamento dei pazienti con aritmie ventricolari e la prevenzione della morte cardiaca improvvisa: Task Force per il Trattamento dei Pazienti con Aritmie Ventricolari e la Prevenzione della Morte Cardiaca Improvvisa della Società Europea di Cardiologia (ESC)

Author

Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Bloma, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., Kirchhof, P., Kjeldsen, K., Kuck, K. -H, Hernandez-Madrid, A., Nikolaou, N., Norekvål, T. M., Spaulding, C., Veldhuisen, D. J., Kolh, P., Lip, G. Y. H., Agewall, S., Barón-Esquivias, G., Boriani, G., Budts, W., Bueno, H., Davide Capodanno, Carerj, S., Crespo-Leiro, M. G., Czerny, M., Deaton, C., Dobrev, D., Erol, Ç, Galderisi, M., Gorenek, B., Kriebel, T., Lambiase, P., Lancellotti, P., Lane, D. A., Lang, I., Manolis, A. J., Morais, J., Moreno, J., Piepoli, M. F., Rutten, F. H., Sredniawa, B., Zamorano, J. L., and Zannad, F.

Subjects
Cardiac resynchronization therapy, Cardiomyopathy, Resuscitation, Heart failure, Guidelines, Valvular heart disease, Defibrillator, Myocardial infarction, Sudden cardiac death, Tachycardia, Implantable cardioverter defibrillator, Ventricular arrhythmia, Stable coronary artery disease, Acute coronary syndrome, Cardiology and Cardiovascular Medicine, Congenital heart disease
Published
2016

168. The value of a new cardiac magnetic resonance imaging protocol in Myocardial Infarction with Non-obstructive Coronary Arteries (MINOCA) - a case-control study using historical controls from a previous study with similar inclusion criteria.

Author

Tornvall, Per, Brolin, E. B., Caidahl, K., Cederlund, K., Collste, O., Daniel, M., Ekenbäck, C., Jensen, J., Y.-Hassan, S., Henareh, L., Hofman-Bang, C., Lyngå, P., Maret, E., Sarkar, N., Spaak, J., Sundqvist, M., Sörensson, P., Ugander, M., and Agewall, S.

Subjects
CARDIAC magnetic resonance imaging, MYOCARDIAL infarction diagnosis, CORONARY disease, ETIOLOGY of diseases, CORONARY angiography, RESEARCH, PREDICTIVE tests, RESEARCH methodology, MAGNETIC resonance imaging, CASE-control method, EVALUATION research, MEDICAL cooperation, MEDICAL protocols, COMPARATIVE studies, QUALITY of life, QUESTIONNAIRES, CONTROL groups
Abstract

Background: Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) is common with a prevalence of 6% of all patients fulfilling the diagnosis of myocardial infarction. MINOCA should be considered a working diagnosis. Cardiac Magnetic Resonance (CMR) imaging has recently been suggested to be of great value to determine the cause behind MINOCA. The objectives of this paper are to describe the rationale behind the second Stockholm Myocardial Infarction with Normal Coronaries (SMINC-2) study and to discuss the protocol for investigation of MINOCA patients in the light of the recently published position paper from the European Society of Cardiology.Methods: The SMINC-2 study is an open non-randomised study using historical controls for comparison. The primary aim is to prove that MINOCA patients investigated with the latest CMR imaging technique can achieve a diagnosis in 70% of all cases entirely by imaging. By including 150 patients we will have >80% chance to prove that the diagnostic accuracy can be improved by 20 absolute % with a p-value of less than 0.05 when compared with CMR imaging in the SMINC-1 study. Furthermore, in addition to invasive coronary angiography, coronary arteries are evaluated by computed tomography angiography to investigate coronary causes and questionnaires are used to describe Quality-of-Life (QoL). By January 1st 2017, 75 patients have been included.Discussion: Whether CMR imaging can provide a diagnosis to an adequate proportion of MINOCA patients is unknown. Well-defined inclusion and exclusion criteria will be used to compare a MINOCA cohort from the population with an appropriate control group. Positive results are likely to influence future guidelines of the management of MINOCA. Furthermore, the study will give mechanistic insights into MINOCA in particular in patients with "true" myocardial infarction and describe QoL in this vulnerable group of patients.Trial Registration: Clinical Trials NCT02318498 . [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

170. Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.

Author

Nordenskjöld AM, Agewall S, Atar D, Baron T, Beltrame J, Bergström O, Erlinge D, Gale CP, López-Pais J, Jernberg T, Johansson P, Ravn-Fisher A, Reynolds HR, Somaratne JB, Tornvall P, and Lindahl B

Subjects
Female, Humans, Male, Middle Aged, Angina, Unstable, Atrial Fibrillation, Australia, Cause of Death, Coronary Vessels, Heart Failure drug therapy, Heart Failure prevention & control, Ischemic Stroke drug therapy, Ischemic Stroke prevention & control, Patient Readmission, Prospective Studies, Sample Size, Stroke Volume physiology, Sweden, Ventricular Function, Left physiology, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Adrenergic beta-Antagonists therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Myocardial Infarction drug therapy, Myocardial Infarction mortality, Myocardial Infarction prevention & control, Secondary Prevention methods
Abstract

Myocardial infarction with non-obstructive coronary arteries (MINOCA) is common and occurs in 6-8% of all patients fulfilling the diagnostic criteria for acute myocardial infarction (AMI). This paper describes the rationale behind the trial 'Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment (ACEI/ARB) of MINOCA patients' (MINOCA-BAT) and the need to improve the secondary preventive treatment of MINOCA patients. METHODS: MINOCA-BAT is a registry-based, randomized, parallel, open-label, multicenter trial with 2:2 factorial design. The primary aim is to determine whether oral beta blockade compared with no oral beta blockade, and ACEI/ARB compared with no ACEI/ARB, reduce the composite endpoint of death of any cause, readmission because of AMI, ischemic stroke or heart failure in patients discharged after MINOCA without clinical signs of heart failure and with left ventricular ejection fraction ≥40%. A total of 3500 patients will be randomized into four groups; e.g. ACEI/ARB and beta blocker, beta blocker only, ACEI/ARB only and neither ACEI/ARB nor beta blocker, and followed for a mean of 4 years. SUMMARY: While patients with MINOCA have an increased risk of serious cardiovascular events and death, whether conventional secondary preventive therapies are beneficial has not been assessed in randomized trials. There is a limited basis for guideline recommendations in MINOCA. Furthermore, studies of routine clinical practice suggest that use of secondary prevention therapies in MINOCA varies considerably. Thus results from this trial may influence future treatment strategies and guidelines specific to MINOCA patients., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

173. Gender differences in the effects of cardiovascular drugs

Author

Tamargo, J, primary, Rosano, G, additional, Walther, T, additional, Duarte, J, additional, Niessner, A, additional, Kaski, JC, additional, Ceconi, C, additional, Drexel, H, additional, Kjeldsen, K, additional, Savarese, G, additional, Torp-Pedersen, C, additional, Atar, D, additional, Lewis, BS, additional, and Agewall, S, additional

Published
2017
Full Text
View/download PDF

174. Wytyczne ESC dotyczące postępowania u pacjentów z komorowymi zaburzeniami rytmu oraz zapobiegania nagłym zgonom sercowym w 2015 roku

Author

Priori, S. G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., Kirchhof, P., Kjeldsen, K., Kuck, K. -H., Hernandez-Madrid, A., Nikolaou, N., Norekva, T. M., Spaulding, C., Van Veldhuisen, D. J., Kolh, P., Lip, G. Y. H., Agewall, S., Baron-Esquivias, G., Boriani, G., Budts, W., Bueno, H., Capodanno, D., Carerj, S., Crespo-Leiro, M. G., Czerny, M., Deaton, C., Dobrev, D., Erol, C., Galderisi, M., Gorenek, B., Kriebel, T., Lambiase, P., Lancellotti, P., Lane, D. A., Lang, I., Manolis, A. J., Morais, J., Moreno, J., Piepoli, M. F., Rutten, F. H., Sredniawa, B., Zamorano, J. L., and Zannad, F.

Published
2015

176. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

Author

Roffi, M, PATRONO, CARLO, Collet, J, Mueller, C, Valgimigli, M, ANDREOTTI, FELICITA, Bax, JJ, Borger, MA, Brotons, C, Chew, DP, Gencer, B, Hasenfuss, G, Kjeldsen, K, Lancellotti, P, Landmesser, U, Mehilli, J, Mukherjee, D, Storey, RF, Windecker, S, Baumgartner, H, Gaemperli, O, Achenbach, S, Agewall, S, Badimon, L, Baigent, C, Bueno, H, Bugiardini, R, Carerj, S, Casselman, F, Cuisset, T, Erol, Ç, Fitzsimons, D, Halle, M, Hamm, C, Hildick-Smith, D, Huber, K, Iliodromitis, E, James, S, Lewis, BS, Lip, GYH, Piepoli, MF, Richter, D, Rosemann, T, Sechtem, U, Steg, PG, Vrints, C, Luis Zamorano, J, Roffi, M, PATRONO, CARLO, Collet, J, Mueller, C, Valgimigli, M, ANDREOTTI, FELICITA, Bax, JJ, Borger, MA, Brotons, C, Chew, DP, Gencer, B, Hasenfuss, G, Kjeldsen, K, Lancellotti, P, Landmesser, U, Mehilli, J, Mukherjee, D, Storey, RF, Windecker, S, Baumgartner, H, Gaemperli, O, Achenbach, S, Agewall, S, Badimon, L, Baigent, C, Bueno, H, Bugiardini, R, Carerj, S, Casselman, F, Cuisset, T, Erol, Ç, Fitzsimons, D, Halle, M, Hamm, C, Hildick-Smith, D, Huber, K, Iliodromitis, E, James, S, Lewis, BS, Lip, GYH, Piepoli, MF, Richter, D, Rosemann, T, Sechtem, U, Steg, PG, Vrints, C, and Luis Zamorano, J

Published
2016

177. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

Author

Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corrà, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Hobbs, F, Løchen, M, Löllgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, Van Der Worp, H, Van Dis, I, Verschuren, W, Binno, S, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Achenbach, S, Badimon, L, Barón-Esquivias, G, Baumgartner, H, Bax, J, Dean, V, Erol, Ç, Gaemperli, O, Kolh, P, Lancellotti, P, Nihoyannopoulos, P, Torbicki, A, Carneiro, A, Metzler, B, Najafov, R, Stelmashok, V, De Maeyer, C, Dilić, M, Gruev, I, Miličić, D, Vaverkova, H, Gustafsson, I, Attia, I, Duishvili, D, Ferrières, J, Kostova, N, Klimiashvili, Z, Hambrecht, R, Tsioufis, K, Szabados, E, Andersen, K, Vaughan, C, Zafrir, B, Novo, S, Davletov, K, Jashari, F, Kerimkulova, A, Mintale, I, Saade, G, Petrulioniene, Z, Delagardelle, C, Magri, C, Rudi, V, Oukerraj, L, Çölkesen, B, Schirmer, H, Dos Reis, R, Gherasim, D, Nedogoda, S, Zavatta, M, Giga, V, Filipova, S, Padial, L, Kiessling, A, Mahdhaoui, A, Ural, D, Nesukay, E, Gale, C, Piepoli, MF, Hoes, AW, Catapano, AL, Cooney, MT, Hall, MS, Hobbs, FDR, Løchen, ML, Richter, DJ, Van Der Worp, HB, Verschuren, WM M, Cho, Le, Franco, OH, Lip, GYH, Bermudo, FM, Zamorano, JL, Bax, JJ, Carneiro, AV, Magri, CJ, Çölkesen, BE, Dos Reis, RP, Padial, LR, Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corrà, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Hobbs, F, Løchen, M, Löllgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, Van Der Worp, H, Van Dis, I, Verschuren, W, Binno, S, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Achenbach, S, Badimon, L, Barón-Esquivias, G, Baumgartner, H, Bax, J, Dean, V, Erol, Ç, Gaemperli, O, Kolh, P, Lancellotti, P, Nihoyannopoulos, P, Torbicki, A, Carneiro, A, Metzler, B, Najafov, R, Stelmashok, V, De Maeyer, C, Dilić, M, Gruev, I, Miličić, D, Vaverkova, H, Gustafsson, I, Attia, I, Duishvili, D, Ferrières, J, Kostova, N, Klimiashvili, Z, Hambrecht, R, Tsioufis, K, Szabados, E, Andersen, K, Vaughan, C, Zafrir, B, Novo, S, Davletov, K, Jashari, F, Kerimkulova, A, Mintale, I, Saade, G, Petrulioniene, Z, Delagardelle, C, Magri, C, Rudi, V, Oukerraj, L, Çölkesen, B, Schirmer, H, Dos Reis, R, Gherasim, D, Nedogoda, S, Zavatta, M, Giga, V, Filipova, S, Padial, L, Kiessling, A, Mahdhaoui, A, Ural, D, Nesukay, E, Gale, C, Piepoli, MF, Hoes, AW, Catapano, AL, Cooney, MT, Hall, MS, Hobbs, FDR, Løchen, ML, Richter, DJ, Van Der Worp, HB, Verschuren, WM M, Cho, Le, Franco, OH, Lip, GYH, Bermudo, FM, Zamorano, JL, Bax, JJ, Carneiro, AV, Magri, CJ, Çölkesen, BE, Dos Reis, RP, and Padial, LR

Published
2016

178. 2016 European Guidelines on cardiovascular disease prevention in clinical practice the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Author

Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corra, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Richard Hobbs, F, Løchen, M, Lollgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, Bart Van Der Worp, H, Van Dis, I, Monique Verschuren, W, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Bueno, H, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Ryden, L, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Piepoli, Massimo F., Hoes, Arno W., Agewall, Stefan, Albus, Christian, Brotons, Carlos, Catapano, Alberico L., Cooney, Marie-Therese, Corra, Ugo, Cosyns, Bernard, Deaton, Christi, Graham, Ian, Hall, Michael Stephen, Richard Hobbs, F. D., Løchen, Maja-Lisa, Lollgen, Herbert, Marques-Vidal, Pedro, Perk, Joep, Prescott, Eva, Redon, Josep, Richter, Dimitrios J., Sattar, Naveed, Smulders, Yvo, Tiberi, Monica, Bart Van Der Worp, H., Van Dis, Ineke, Monique Verschuren, W. M., De Backer, Guy, Roffi, Marco, Aboyans, Victor, Bachl, Norbert, Bueno, Hector, Carerj, Scipione, Cho, Leslie, Cox, John, De Sutter, Johan, Egidi, Gunther, Fisher, Miles, Fitzsimons, Donna, Franco, Oscar H., Guenoun, Maxime, Jennings, Catriona, Jug, Borut, Kirchhof, Paulus, Kotseva, Kornelia, Lip, Gregory Y. H., MacH, Francois, Mancia, Giuseppe, Bermudo, Franz Martin, Mezzani, Alessandro, Niessner, Alexander, Ponikowski, Piotr, Rauch, Bernhard, Ryden, Lars, Stauder, Adrienne, Turc, Guillaume, Wiklund, Olov, Windecker, Stephan, Zamorano, Jose Luis, Piepoli, M, Hoes, A, Agewall, S, Albus, C, Brotons, C, Catapano, A, Cooney, M, Corra, U, Cosyns, B, Deaton, C, Graham, I, Hall, M, Richard Hobbs, F, Løchen, M, Lollgen, H, Marques-Vidal, P, Perk, J, Prescott, E, Redon, J, Richter, D, Sattar, N, Smulders, Y, Tiberi, M, Bart Van Der Worp, H, Van Dis, I, Monique Verschuren, W, De Backer, G, Roffi, M, Aboyans, V, Bachl, N, Bueno, H, Carerj, S, Cho, L, Cox, J, De Sutter, J, Egidi, G, Fisher, M, Fitzsimons, D, Franco, O, Guenoun, M, Jennings, C, Jug, B, Kirchhof, P, Kotseva, K, Lip, G, Mach, F, Mancia, G, Bermudo, F, Mezzani, A, Niessner, A, Ponikowski, P, Rauch, B, Ryden, L, Stauder, A, Turc, G, Wiklund, O, Windecker, S, Zamorano, J, Piepoli, Massimo F., Hoes, Arno W., Agewall, Stefan, Albus, Christian, Brotons, Carlos, Catapano, Alberico L., Cooney, Marie-Therese, Corra, Ugo, Cosyns, Bernard, Deaton, Christi, Graham, Ian, Hall, Michael Stephen, Richard Hobbs, F. D., Løchen, Maja-Lisa, Lollgen, Herbert, Marques-Vidal, Pedro, Perk, Joep, Prescott, Eva, Redon, Josep, Richter, Dimitrios J., Sattar, Naveed, Smulders, Yvo, Tiberi, Monica, Bart Van Der Worp, H., Van Dis, Ineke, Monique Verschuren, W. M., De Backer, Guy, Roffi, Marco, Aboyans, Victor, Bachl, Norbert, Bueno, Hector, Carerj, Scipione, Cho, Leslie, Cox, John, De Sutter, Johan, Egidi, Gunther, Fisher, Miles, Fitzsimons, Donna, Franco, Oscar H., Guenoun, Maxime, Jennings, Catriona, Jug, Borut, Kirchhof, Paulus, Kotseva, Kornelia, Lip, Gregory Y. H., MacH, Francois, Mancia, Giuseppe, Bermudo, Franz Martin, Mezzani, Alessandro, Niessner, Alexander, Ponikowski, Piotr, Rauch, Bernhard, Ryden, Lars, Stauder, Adrienne, Turc, Guillaume, Wiklund, Olov, Windecker, Stephan, and Zamorano, Jose Luis

Published
2016

179. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration

Author

Willeit, P., Thompson, S., Agewall, S., Bergström, G., Bickel, H., Catapano, A., Chien, K., De Groot, E., Empana, J., Etgen, T., Franco, O., Iglseder, B., Johnsen, S., Kavousi, M., Lind, L., Liu, J., Mathiesen, E., Norata, Giuseppe, Olsen, M., Papagianni, A., Poppert, H., Price, J., Sacco, R., Yanez, D., Zhao, D., Schminke, U., Bülbül, A., Polak, J., Sitzer, M., Hofman, A., Grigore, L., Dörr, M., Su, T., Ducimetière, P., Xie, W., Ronkainen, K., Kiechl, S., Rundek, T., Robertson, C., Fagerberg, B., Bokemark, L., Steinmetz, H., Ikram, M., Völzke, H., Lin, H., Plichart, M., Tuomainen, T., Desvarieux, M., McLachlan, S., Schmidt, C., Kauhanen, J., Willeit, J., Lorenz, M., Sander, D., Willeit, P., Thompson, S., Agewall, S., Bergström, G., Bickel, H., Catapano, A., Chien, K., De Groot, E., Empana, J., Etgen, T., Franco, O., Iglseder, B., Johnsen, S., Kavousi, M., Lind, L., Liu, J., Mathiesen, E., Norata, Giuseppe, Olsen, M., Papagianni, A., Poppert, H., Price, J., Sacco, R., Yanez, D., Zhao, D., Schminke, U., Bülbül, A., Polak, J., Sitzer, M., Hofman, A., Grigore, L., Dörr, M., Su, T., Ducimetière, P., Xie, W., Ronkainen, K., Kiechl, S., Rundek, T., Robertson, C., Fagerberg, B., Bokemark, L., Steinmetz, H., Ikram, M., Völzke, H., Lin, H., Plichart, M., Tuomainen, T., Desvarieux, M., McLachlan, S., Schmidt, C., Kauhanen, J., Willeit, J., Lorenz, M., and Sander, D.

Abstract

© 2014 European Society of Cardiology. Background Large-scale epidemiological evidence on the role of inflammation in early atherosclerosis, assessed by carotid ultrasound, is lacking. We aimed to quantify cross-sectional and longitudinal associations of inflammatory markers with common-carotid-artery intima-media thickness (CCA-IMT) in the general population. Methods Information on high-sensitivity C-reactive protein, fibrinogen, leucocyte count and CCA-IMT was available in 20 prospective cohort studies of the PROG-IMT collaboration involving 49,097 participants free of pre-existing cardiovascular disease. Estimates of associations were calculated within each study and then combined using random-effects meta-analyses. Results Mean baseline CCA-IMT amounted to 0.74 mm (SD = 0.18) and mean CCA-IMT progression over a mean of 3.9 years to 0.011 mm/year (SD = 0.039). Cross-sectional analyses showed positive linear associations between inflammatory markers and baseline CCA-IMT. After adjustment for traditional cardiovascular risk factors, mean differences in baseline CCA-IMT per one-SD higher inflammatory marker were: 0.0082 mm for high-sensitivity C-reactive protein (p < 0.001); 0.0072 mm for fibrinogen (p < 0.001); and 0.0025 mm for leucocyte count (p = 0.033). 'Inflammatory load', defined as the number of elevated inflammatory markers (i.e. in upper two quintiles), showed a positive linear association with baseline CCA-IMT (p < 0.001). Longitudinal associations of baseline inflammatory markers and changes therein with CCA-IMT progression were null or at most weak. Participants with the highest 'inflammatory load' had a greater CCA-IMT progression (p = 0.015). Conclusion Inflammation was independently associated with CCA-IMT cross-sectionally. The lack of clear associations with CCA-IMT progression may be explained by imprecision in its assessment within a limited time period. Our findings for 'inflammatory load' suggest important combined effects of the three

Published
2016

180. Myocardial revascularization

Author

Wijns, W., Kolh, P., Danchin, N., Mario, C. di, Falk, V., Folliguet, T., Garg, S., Huber, K., James, S., Knuuti, J., Lopez-Sendon, J., Marco, J., Menicanti, L., Ostojic, M., Piepoli, M.F., Pirlet, C., Pomar, J.L., Reifart, N., Ribichini, F.L., Schalij, M.J., Sergeant, P., Serruys, P.W., Silber, S., Uva, M.S., Taggart, D., Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., Popescu, B.A., Reiner, Z., Sechtem, U., Sirnes, P.A., Tendera, M., Vardas, P.E., Widimsky, P., Alfieri, O., Dunning, J., Elia, S., Kappetein, P., Lockowandt, U., Sarris, G., Vouhe, P., Segesser, L. von, Agewall, S., Aladashvili, A., Alexopoulos, D., Antunes, M.J., Atalar, E., Riviere, A.B. de la, Doganov, A., Eha, J., Fajadet, J., Ferreira, R., Garot, J., Halcox, J., Hasin, Y., Janssens, S., Kervinen, K., Laufer, G., Legrand, V., Nashef, S.A.M., Neumann, F.J., Niemela, K., Nihoyannopoulos, P., Noc, M., Piek, J.J., Pirk, J., Rozenman, Y., Sabate, M., Starc, R., Thielmann, M., Wheatley, D.J., Windecker, S., Zembala, M., ESC, EACTS, Wijns, W, Kolh, P, Danchin, N, Di Mario, C, Falk, V, Folliguet, T, Garg, S, Huber, K, James, S, Knuuti, J, Lopez Sendon, J, Marco, J, Menicanti, L, Ostojic, M, Piepoli, Mf, Pirlet, C, Pomar, Jl, Reifart, N, Ribichini, Fl, Schalij, Mj, Sergeant, P, Serruys, Pw, Silber, S, Uva, M, Taggart, D, Vahanian, A, Auricchio, A, Bax, J, Ceconi, C, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearney, P, Mcdonagh, T, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, Pe, Widimsky, P, Alfieri, Ottavio, Dunning, J, Elia, S, Kappetein, P, Lockowandt, U, Sarris, G, Vouhe, P, von Segesser, L, Agewall, S, Aladashvili, A, Alexopoulos, D, Antunes, Mj, Atalar, E, de la Riviere, Ab, Doganov, A, Eha, J, Fajadet, J, Ferreira, R, Garot, J, Halcox, J, Hasin, Y, Janssens, S, Kervinen, K, Laufer, G, Legrand, V, Nashef, Sam, Neumann, Fj, Niemela, K, Nihoyannopoulos, P, Noc, M, Piek, Jj, Pirk, J, Rozenman, Y, Sabate, M, Starc, R, Thielmann, M, Wheatley, Dj, Windecker, S, and Zembala, M.

Published
2011

181. Oral antiplatelet agents in ACS: from pharmacology to clinical differences

Author

Agewall, S, Badimon, L, Drouet, L, Eschenhagen, T, Husted, S, Simon, T, and Steg, G

Subjects
cardiovascular diseases
Abstract

Antiplatelet agents play an essential role in the treatment of acute coronary syndrome (ACS). Numerous clinical trials have established the value of antiplatelet therapies for ACS. Aspirin (ASA), thienopyridines and GP IIb/IIIa antagonists comprise the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS. Thienopyridines are a class of drugs that function via inhibition of the adenosine diphosphate (ADP) P2Y12 platelet receptors. Currently, clopidogrel, a second generation thienopyridine, is the main drug of choice and the combination of aspirin and clopidogrel is administered orally for the treatment of ACS. Recently, a third generation of thienopyridines has been introduced represented by prasugrel that has demonstrated promising results in ACS patients treated with percutaneous coronary intervention (PCI). A number of nonthienopyridine oral antiplatelet drugs are under development, and one of them, ticagrelor has already been tested in a major phase III clinical trial, PLATO, with the inclusion of a broad spectrum of patients with ACS. The present review aims to discuss the present knowledge about the safety and efficacy of oral antiplatelet treatment of patients with ACS.

Published
2011
Full Text
View/download PDF

182. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Author

Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Storey RF, Wood D, ESC Committee for Practice Guidelines 2008–2010, 2010–2012 Committees, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Document Reviewers, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano J.L., PERRONE FILARDI, PASQUALE, RICCARDI, GABRIELE, Reiner, Z, Catapano, Al, De Backer, G, Graham, I, Taskinen, Mr, Wiklund, O, Agewall, S, Alegria, E, Chapman, Mj, Durrington, P, Erdine, S, Halcox, J, Hobbs, R, Kjekshus, J, PERRONE FILARDI, Pasquale, Riccardi, Gabriele, Storey, Rf, Wood, D, ESC Committee for Practice Guidelines, 2008–2010, 2010–2012, Committee, Bax, J, Vahanian, A, Auricchio, A, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Filippatos, G, Funck Brentano, C, Hasdai, D, Hoes, A, Kearney, P, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Poldermans, D, Popescu, Ba, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vardas, P, Widimsky, P, Windecker, S, Document, Reviewers, Berkenboom, G, De Graaf, J, Descamps, O, Gotcheva, N, Griffith, K, Guida, Gf, Gulec, S, Henkin, Y, Huber, K, Kesaniemi, Ya, Lekakis, J, Manolis, Aj, Marques Vidal, P, Masana, L, Mcmurray, J, Mendes, M, Pagava, Z, Pedersen, T, Prescott, E, Rato, Q, Rosano, G, Sans, S, Stalenhoef, A, Tokgozoglu, L, Viigimaa, M, Wittekoek, Me, Zamorano, J. L., Alberico L., Catapano, Željko, Reiner, Guy De, Backer, Ian, Graham, Marja Riitta, Taskinen, Olov, Wiklund, Stefan, Agewall, Eduardo, Alegria, M., John Chapman, Paul, Durrington, Serap, Erdine, Julian, Halcox, Richard, Hobb, John, Kjekshu, Robert F., Storey, and David, Wood

Subjects
Male, Nice, Type 2 diabetes, Disease, Coronary artery disease, Risk Factors, Health care, Secondary Prevention, Child, Societies, Medical, media_common, computer.programming_language, Hypolipidemic Agents, Clinical Trials as Topic, Middle Aged, Lipids, Europe, Primary Prevention, Cholesterol, Cardiovascular Diseases, Practice Guidelines as Topic, Female, Cardiology and Cardiovascular Medicine, Risk assessment, Risk, Adult, medicine.medical_specialty, Adolescent, Genotype, Lipoproteins, Advisory Committees, Cardiology, Guidelines as Topic, Risk Assessment, Specimen Handling, Sex Factors, Internal medicine, Weight Loss, medicine, media_common.cataloged_instance, Humans, cardiovascular diseases, European union, Intensive care medicine, Exercise, Life Style, Health aging / healthy living Cardiovascular diseases [IGMD 5], Aged, Dyslipidemias, Transplantation, business.industry, Guideline, medicine.disease, Atherosclerosis, Lipid Metabolism, Dietary Fats, Diet, Endocrinology, Early Diagnosis, Dietary Supplements, Kidney Failure, Chronic, Patient Compliance, business, Energy Intake, computer, Lipoprotein(a)
Abstract

Item does not contain fulltext Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.

Published
2011
Full Text
View/download PDF

183. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Author

Hamm, Cw, Bassand, Jp, Agewall, S, Bax, J, Boersma, E, Bueno, H, Caso, P, Dudek, D, Gielen, S, Huber, K, Ohman, M, Petrie, Mc, Sonntag, F, Uva, Ms, Storey, Rf, Wijns, W, Zahger, D, ESC Committee for Practice Guidelines, Bax, Jj, Auricchio, A, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Poldermans, D, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Achenbach, S, Badimon, L, Bertrand, M, Bøtker, He, Collet, Jp, Crea, F, Danchin, N, Falk, E, Goudevenos, J, Gulba, D, Hambrecht, R, Herrmann, J, Kastrati, A, Kjeldsen, K, Kristensen, Sd, Lancellotti, P, Mehilli, J, Merkely, B, Montalescot, G, Neumann, Fj, Neyses, L, Perk, J, Roffi, M, Romeo, F, Ruda, M, Swahn, E, Valgimigli, M, Vrints, Cj, Widimsky, P., and Neyses, Ludwig [collaborator]

Subjects
unstable angina, Male, Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors, Diabetic Cardiomyopathies, Platelet Aggregation Inhibitors/therapeutic use, heparin, Diagnostic Imaging/methods, Myocardial Revascularization, ST segment, Myocardial Revascularization/methods, guidelines, Angioplasty, Balloon, Coronary, Biological Markers/blood, Coronary Artery Bypass, Aged, 80 and over, Evidence-Based Medicine, diabetes, bivalirudin, troponin, Age Factors, Diabetic Cardiomyopathies/diagnosis/therapy, angioplasty, enoxaparin, Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine], Prognosis, Angioplasty, Balloon, Coronary/methods, Anticoagulants/therapeutic use, Cardiology, Biological Markers, Female, Cardiology and Cardiovascular Medicine, Physical Examination/methods, Diagnostic Imaging, medicine.medical_specialty, Cardiotonic Agents, aspirin, non-ST-elevation myocardial infarction, Hemorrhage, Platelet Glycoprotein GPIIb-IIIa Complex, Risk Assessment, Acute Coronary Syndrome/diagnosis/etiology/*therapy, acute coronary syndrome, European Society of Cardiology, ticagrelor, Diagnosis, Differential, Internal medicine, chest pain unit, medicine, Humans, In patient, Hemorrhage/etiology, Acute Coronary Syndrome, Physical Examination, Aged, clopidogrel, Management of acute coronary syndrome, Task force, business.industry, Acute Coronary Syndrome/diagnosis/etiology/therapy, fondaparinux, Elevation, Anticoagulants, Long-Term Care, Cardiotonic Agents/therapeutic use, prasugrel, bypass surgery, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, stent, Cardiovascular & respiratory systems [D03] [Human health sciences], business, Biomarkers, Biomarkers/blood, Platelet Aggregation Inhibitors
Abstract

Eur Heart J

Published
2011
Full Text
View/download PDF

184. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Author

Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Storey RF, Wood D, European Society of Cardiology, European Atherosclerosis S.o.c.i.e.t.y., RICCARDI, GABRIELE, Catapano, Al, Reiner, Z, De Backer, G, Graham, I, Taskinen, Mr, Wiklund, O, Agewall, S, Alegria, E, Chapman, M, Durrington, P, Erdine, S, Halcox, J, Hobbs, R, Kjekshus, J, Filardi, Pp, Riccardi, Gabriele, Storey, Rf, Wood, D, European Society of, Cardiology, European Atherosclerosis, Society, and European Atherosclerosis, S. o. c. i. e. t. y.

Published
2011

185. ESC/EAS Guidelines for the management of dyslipidaemias

Author

Reiner Z, Catapano AL, De Baker G, Graham I, Taskinen MR, Wiklund O, Agewall S, Algeria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbis RH, Kjekshus JK, Perrone Filardi P, Storey RF, David W., RICCARDI, GABRIELE, Reiner, Z, Catapano, Al, De Baker, G, Graham, I, Taskinen, Mr, Wiklund, O, Agewall, S, Algeria, E, Chapman, Mj, Durrington, P, Erdine, S, Halcox, J, Hobbis, Rh, Kjekshus, Jk, Perrone Filardi, P, Riccardi, Gabriele, Storey, Rf, and David, W.

Published
2011

186. ESC/EAS Guidelines for the management of dyslipidaemias (vol 32, pg 1769, 2011)

Author

Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Riccardi G, Storey RF, Wood D., PERRONE FILARDI, PASQUALE, Catapano, Al, Reiner, Z, De Backer, G, Graham, I, Taskinen, Mr, Wiklund, O, Agewall, S, Alegria, E, Chapman, M, Durrington, P, Erdine, S, Halcox, J, Hobbs, R, Kjekshus, J, PERRONE FILARDI, Pasquale, Riccardi, G, Storey, Rf, and Wood, D.

Published
2011

189. Guidelines on myocardial revascularization

Author

Task Force on Myocardial Revascularization of the European Society of Cardiology, the European Association for Cardio Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Collaborators: Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck Bretano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouohe P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, de la Riviere AB, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M., ALFIERI , OTTAVIO, ACS - Amsterdam Cardiovascular Sciences, Cardiology, Task Force on Myocardial Revascularization of the European Society of, Cardiology, the European Association for Cardio Thoracic, Surgery, European Association for Percutaneous Cardiovascular, Intervention, Kolh, P, Wijns, W, Danchin, N, Di Mario, C, Falk, V, Folliguet, T, Garg, S, Huber, K, James, S, Knuuti, J, Lopez Sendon, J, Marco, J, Menicanti, L, Ostojic, M, Piepoli, Mf, Pirlet, C, Pomar, Jl, Reifart, N, Ribichini, Fl, Schalij, Mj, Sergeant, P, Serruys, Pw, Silber, S, Sousa Uva, M, Taggart D., Collaborators: Vahanian A, Auricchio, A, Bax, J, Ceconi, C, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearney, P, Mcdonagh, T, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, Pe, Widimsky, P, Alfieri, Ottavio, Dunning, J, Elia, S, Kappetein, P, Lockowandt, U, Sarris, G, Vouhe, P, von Segesser, L, Agewall, S, Aladashvili, A, Alexopoulos, D, Antunes, Mj, Atalar, E, de la Riviere, Ab, Doganov, A, Eha, J, Fajadet, J, Ferreira, R, Garot, J, Halcox, J, Hasin, Y, Janssens, S, Kervinen, K, Laufer, G, Legrand, V, Nashef, Sa, Neumann, Fj, Niemela, K, Nihoyannopoulos, P, Noc, M, Piek, Jj, Pirk, J, Rozenman, Y, Sabate, M, Starc, R, Thielmann, M, Wheatley, Dj, Windecker, S, Zembala, M., Funck Bretano, C, and Vouohe, P

Subjects
Carotid Artery Diseases, Graft Rejection, lcsh:Diseases of the circulatory (Cardiovascular) system, Judgement, Settore MED/21 - Chirurgia Toracica, Medizin, Heart Valve Diseases, Myocardial Ischemia, Contrast Media, Myocardial Revascularization, Assisted Circulation, General Environmental Science, Drug-Eluting Stents, General Medicine, Prognosis, Europe, Stroke, Acute Disease, Cardiology, Platelet aggregation inhibitor, Kidney Diseases, Medical emergency, Cardiology and Cardiovascular Medicine, Risk assessment, Pulmonary and Respiratory Medicine, Diagnostic Imaging, medicine.medical_specialty, Myocardial revascularization, MEDLINE, Renal Artery Obstruction, Risk Assessment, End stage renal disease, Blood Vessel Prosthesis Implantation, Fibrinolytic Agents, Patient Education as Topic, Internal medicine, Preoperative Care, medicine, Humans, Hypoglycemic Agents, Heart Failure, Postoperative Care, business.industry, Contraindications, Conflict of interest, Arrhythmias, Cardiac, Evidence-based medicine, medicine.disease, lcsh:RC666-701, Chronic Disease, General Earth and Planetary Sciences, Surgery, business, Fibrinolytic agent, Diabetic Angiopathies, Platelet Aggregation Inhibitors
Abstract

Guidelines and Expert Consensus Documents summarize and evaluate all available evidence with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk benefit ratio of diagnostic or therapeutic means. Guidelines are no substitutes for textbooks and their legal implications have been discussed previously. Guidelines and recommendations should help physicians to make decisions in their daily practice. However, the ultimate judgement regarding the care of an individual patient must be made by his/her responsible physician(s). The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/ guidelines/rules). Members of this Task Force were selected by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) to represent all physicians involved with the medical and surgical care of patients with coronary artery disease (CAD). A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk benefit ratio. Estimates of expected health outcomes for society are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2. The members of the Task Force have provided disclosure statements of all relationships that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at European Heart House, headquarters of the ESC. Any changes in conflict of interest that arose during the writing period were notified to the ESC. The Task Force report received its entire financial support from the ESC and EACTS, without any involvement of the pharmaceutical, device, or surgical industry. ESC and EACTS Committees for Practice Guidelines are responsible for the endorsement process of these joint Guidelines. The finalized document has been approved by all the experts involved in the Task Force, and was submitted to outside specialists selected by both societies for review. The document is revised, and finally approved by ESC and EACTS and subsequently published simultaneously in the European Heart Journal and the European Journal of Cardio-Thoracic Surgery. After publication, dissemination of the Guidelines is of paramount importance. Pocket-sized versions and personal digital assistant-downloadable versions are useful at the point of care. Some surveys have shown that the intended users are sometimes unaware of the existence of guidelines, or simply do not translate them into practice. Thus, implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Published
2010

190. Focus on blood pressure and risk factor intervention.

Author

Agewall S

Subjects
Antihypertensive Agents adverse effects, Heart Disease Risk Factors, Humans, Hypertension mortality, Hypertension physiopathology, Risk Assessment, Treatment Outcome, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Hypertension drug therapy
Published
2020
Full Text
View/download PDF

192. Minimizing bleeding events.

Author

Agewall S

Subjects
Angiotensin II Type 1 Receptor Blockers therapeutic use, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anticoagulants adverse effects, Antiviral Agents therapeutic use, COVID-19, Coronavirus Infections drug therapy, Coronavirus Infections virology, Dual Anti-Platelet Therapy, Hemorrhage chemically induced, Humans, Pandemics, Platelet Aggregation Inhibitors adverse effects, Pneumonia, Viral drug therapy, Pneumonia, Viral virology, Risk Assessment, COVID-19 Drug Treatment, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Anticoagulants therapeutic use, Hemorrhage prevention & control, Platelet Aggregation Inhibitors therapeutic use
Published
2020
Full Text
View/download PDF

193. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Author

Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, Liao X, Lonn E, Gerstein HC, Yusuf S, Brouwers FP, Asselbergs FW, van Gilst W, Anderssen SA, Grobbee DE, Kastelein JJP, Visseren FLJ, Ntaios G, Hatzitolios AI, Savopoulos C, Nieuwkerk PT, Stroes E, Walters M, Higgins P, Dawson J, Gresele P, Guglielmini G, Migliacci R, Ezhov M, Safarova M, Balakhonova T, Sato E, Amaha M, Nakamura T, Kapellas K, Jamieson LM, Skilton M, Blumenthal JA, Hinderliter A, Sherwood A, Smith PJ, van Agtmael MA, Reiss P, van Vonderen MGA, Kiechl S, Klingenschmid G, Sitzer M, Stehouwer CDA, Uthoff H, Zou ZY, Cunha AR, Neves MF, Witham MD, Park HW, Lee MS, Bae JH, Bernal E, Wachtell K, Kjeldsen SE, Olsen MH, Preiss D, Sattar N, Beishuizen E, Huisman MV, Espeland MA, Schmidt C, Agewall S, Ok E, Aşçi G, de Groot E, Grooteman MPC, Blankestijn PJ, Bots ML, Sweeting MJ, Thompson SG, and Lorenz MW

Subjects
Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Carotid Artery, Common diagnostic imaging, Carotid Intima-Media Thickness, Heart Disease Risk Factors, Myocardial Infarction diagnostic imaging, Stroke diagnostic imaging
Abstract

Background: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk., Methods: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach., Results: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 μm/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87-0.94), with an additional relative risk for CVD of 0.92 (0.87-0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 μm/y would yield relative risks of 0.84 (0.75-0.93), 0.76 (0.67-0.85), 0.69 (0.59-0.79), or 0.63 (0.52-0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients., Conclusions: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.

Published
2020
Full Text
View/download PDF

194. Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome?

Author

Agewall S

Subjects
Acute Coronary Syndrome blood, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome mortality, Clinical Decision-Making, Humans, Patient Selection, Pharmacogenomic Variants, Platelet Aggregation Inhibitors adverse effects, Risk Assessment, Risk Factors, Treatment Outcome, Acute Coronary Syndrome therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Platelet Aggregation Inhibitors therapeutic use, Precision Medicine
Published
2020
Full Text
View/download PDF

196. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.

Author

Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, and Agewall S

Subjects
Biomarkers blood, Blood Glucose metabolism, Cardiovascular Diseases diagnosis, Cardiovascular Diseases mortality, Diabetes Mellitus blood, Diabetes Mellitus diagnosis, Diabetes Mellitus mortality, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias mortality, Humans, Hypoglycemic Agents adverse effects, Hypolipidemic Agents adverse effects, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Blood Glucose drug effects, Cardiovascular Diseases prevention & control, Diabetes Mellitus drug therapy, Dyslipidemias drug therapy, Endpoint Determination, Hypoglycemic Agents therapeutic use, Hypolipidemic Agents therapeutic use, Lipids blood, Randomized Controlled Trials as Topic methods, Research Design
Abstract

Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

197. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Author

Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, and Meroni PL

Subjects
Algorithms, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid epidemiology, Biomarkers blood, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Clinical Decision Rules, Clinical Decision-Making, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias epidemiology, Humans, Hypolipidemic Agents adverse effects, Risk Assessment, Risk Factors, Risk Reduction Behavior, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Cardiovascular Diseases prevention & control, Dyslipidemias drug therapy, Hypolipidemic Agents therapeutic use, Lipids blood
Abstract

Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have not been determined yet, and recommendations are largely based on expert opinions. In this position paper, we describe abnormalities in lipid metabolism and introduce a new algorithm for estimation of cardiovascular risk (CVR) and LM in RA. The algorithm stratifies patients according to RA-related factors impacting CVR (such as RA activity and severity and medication). We propose strategies for monitoring of lipid parameters and treatment of dyslipidaemia in RA (including lifestyle, statins and other lipid-modifying therapies, and disease modifying antirheumatic drugs). These opinion-based recommendations are meant to facilitate LM in RA until more evidence is available., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

198. Lipids and antithrombotic treatment.

Author

Agewall S

Subjects
Biomarkers blood, Cardiovascular Diseases blood, Cardiovascular Diseases diagnosis, Dyslipidemias blood, Dyslipidemias diagnosis, Fibrinolytic Agents adverse effects, Humans, Hypolipidemic Agents adverse effects, Blood Coagulation drug effects, Cardiovascular Diseases drug therapy, Dyslipidemias drug therapy, Fibrinolytic Agents therapeutic use, Hypolipidemic Agents therapeutic use, Lipids blood
Published
2020
Full Text
View/download PDF

199. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.

Author

Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, and Lewis BS

Subjects
Administration, Oral, Aged, Amputation, Surgical, Anticoagulants adverse effects, Chronic Disease, Dual Anti-Platelet Therapy, Female, Fibrinolytic Agents adverse effects, Hemorrhage chemically induced, Humans, Limb Salvage, Male, Middle Aged, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease mortality, Platelet Aggregation Inhibitors adverse effects, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Stroke mortality, Stroke prevention & control, Time Factors, Treatment Outcome, Anticoagulants administration & dosage, Fibrinolytic Agents administration & dosage, Lower Extremity blood supply, Peripheral Arterial Disease drug therapy, Platelet Aggregation Inhibitors administration & dosage
Abstract

Aims: The role and selection of antithrombotic therapy to improve limb outcomes in chronic lower extremity artery disease (LEAD) is still debated. We conducted a meta-analysis to examine the efficacy and safety of antithrombotic and more intense antithrombotic therapy on limb outcomes and limb salvage in patients with chronic LEAD., Methods and Results: Study inclusion criteria were: enrolment of patients with LEAD, randomized allocation to more vs. less intense antithrombotic therapy [more vs. less intense single-antiplatelet therapy (SAPT); dual-antiplatelet therapy vs. SAPT; dual antithrombotic therapy vs. SAPT or oral anticoagulant]; enrolment of ≥200 patients; reporting of at least one of following outcomes: limb amputation or revascularization. Seven randomized studies enrolling 30 447 patients were included. Over a median follow-up of 24 months, more vs. less intense antithrombotic therapy or placebo significantly reduced the risk of limb revascularization [relative risk (RR) 0.89, 95% confidence interval (CI) 0.83-0.94] and limb amputation (RR 0.63, 95% CI 0.46-0.86), as well as stroke (RR 0.82, 95% CI 0.70-0.97). There was no statistically significant effect on the risk of myocardial infarction (RR 0.98, 95% CI 0.87-1.11), all-cause (RR 0.93, 95% CI 0.86-1.01), and cardiovascular death (RR 0.97, 95% CI 0.86-1.08). Risk of major bleeding increased (RR 1.23, 95% CI 1.04-1.44)., Conclusion: In patients with LEAD, more intense antithrombotic therapy reduces the risk of limb amputation and revascularization as well as stroke with an increase in the risk of bleeding events., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

200. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium.

Author

Bahls M, Lorenz MW, Dörr M, Gao L, Kitagawa K, Tuomainen TP, Agewall S, Berenson G, Catapano AL, Norata GD, Bots ML, van Gilst W, Asselbergs FW, Brouwers FP, Uthoff H, Sander D, Poppert H, Hecht Olsen M, Empana JP, Schminke U, Baldassarre D, Veglia F, Franco OH, Kavousi M, de Groot E, Mathiesen EB, Grigore L, Polak JF, Rundek T, Stehouwer CD, Skilton MR, Hatzitolios AI, Savopoulos C, Ntaios G, Plichart M, McLachlan S, Lind L, Willeit P, Steinmetz H, Desvarieux M, Ikram MA, Johnsen SH, Schmidt C, Willeit J, Ducimetiere P, Price JF, Bergström G, Kauhanen J, Kiechl S, Sitzer M, Bickel H, Sacco RL, Hofman A, Völzke H, and Thompson SG

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult, Biomarkers blood, Carotid Intima-Media Thickness, Cholesterol, HDL blood, Cholesterol, LDL blood, Disease Progression, Heart Disease Risk Factors, Myocardial Infarction epidemiology, Predictive Value of Tests, Prognosis, Risk Assessment, Stroke epidemiology, Time Factors, Blood Pressure, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases mortality, Carotid Artery Diseases diagnostic imaging, Carotid Artery Diseases epidemiology, Carotid Artery Diseases mortality, Cholesterol blood, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias epidemiology, Dyslipidemias mortality, Hypertension diagnosis, Hypertension epidemiology, Hypertension mortality, Hypertension physiopathology
Abstract

Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional risk factors is unclear., Methods and Results: An individual participant meta-analysis was used to associate the annualised progression of systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with future cardiovascular disease risk in 13 prospective cohort studies of the PROG-IMT collaboration ( n  = 34,072). Follow-up data included information on a combined cardiovascular disease endpoint of myocardial infarction, stroke, or vascular death. In secondary analyses, annualised progression was replaced with average. Log hazard ratios per standard deviation difference were pooled across studies by a random effects meta-analysis. In primary analysis, the annualised progression of total cholesterol was marginally related to a higher cardiovascular disease risk (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.00 to 1.07). The annualised progression of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol was not associated with future cardiovascular disease risk. In secondary analysis, average systolic blood pressure (HR 1.20 95% CI 1.11 to 1.29) and low-density lipoprotein cholesterol (HR 1.09, 95% CI 1.02 to 1.16) were related to a greater, while high-density lipoprotein cholesterol (HR 0.92, 95% CI 0.88 to 0.97) was related to a lower risk of future cardiovascular disease events., Conclusion: Averaged measurements of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol displayed significant linear relationships with the risk of future cardiovascular disease events. However, there was no clear association between the annualised progression of these conventional risk factors in individuals with the risk of future clinical endpoints.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results